IgAN severity, including eGFR, hypertension and Oxford-T scores. In addition, ACR, but not PCR and 24h UPE, presented with positive association with Oxford-S scores. In univariate survival analysis, ACR, PCR, as well as 24h UPE were significantly associated with long term renal outcome. When comparing the performance of ACR, PCR and 24h UPE in predicting IgAN prognosis, ACR had consistently better performance than two other measurements, as represented by higher AUC using time-dependent survival analysis. When adjusted for well known risk factors for IgAN progression, including eGFR, hypertension, histological lesions and therapy, only ACR were still significantly associated with poor renal outcome of IgAN (HR: 2.230 (1.452e3.424), P < 0.001). On contrary, PCR and 24h UPE were not associated with long term renal outcome after adjusting. Results: A total of 1052 cases were included. There was an equal proportion of male and female (50.4% vs 49.6%). The mean age at the time of renal biopsy was 36.86 AE 11.58 years old. Five-year renal survival rate was 92%, and ten-year renal survival rate was 88%. We enrolled 297 cases who were followed up for 5 years. These patients were divided into rapid progression and stable progression according to the progress of renal function, we found that cases in rapid
Objective: Immunoglobulin class-switch recombination (CSR) is crucial for the expression of IgA, and plays a vital role in the physiopathology of IgA nephropathy (IgAN) . The aim of the study is to investigatethe effect of poly(I:C) in modulatingTLR3-BAFF axis activation in promoting IgA CSR ofIgAN patients and IgAN rat model. Methods: Blood samples and tonsillar tissue specimens were obtained from 24 patients with IgAN and 26 patients with chronic tonsillitis (CT) as control. We also used the IgAN rat model to investigate the relationship between viral infection and IgA CSR. Results: Immunohistochemical and ELISA Western blotting examination revealed that TLR3/BAFF axis are activated in IgAN patients compared with controls. Synthetic double-stranded RNA Poly(I:C) stimulation up-regulated TACI/ TLR3/TRIF/TRAF6 expression, promote IgA CSR and BAFF productions in tonsilmononuclear cells. TLR3 or BAFF siRNA decreases IgA expression. In IgAN rat models, TLR3/BAFF signaling was highly activated. With 200 mg Poly(I:C) sodiumsalt into the left naris for 8 weeks, IgAwas highly deposited on glomeruli. It also revealed that Poly(I:C) activated TLR3/BAFF axis and IgA CSR in vivo. Conclusion: These data points towards the role of TLR3/BAFF axisin IgA CSR of IgAN, and the data also supports the notion that mucosal immunization with virus infection results in impaired mucosal and systemic IgA responses. Objective: We investigated the clinical characteristics and the relationship between CKD stages and long-term outcomes of patients with primary IgA nephropathy (IgAN) through the retrospective analysis of their clinical data. Methods: Patients with biopsy-proved primary IgAN from January 2002 to December 2013 were included. They were older than 18 years old and their follow-up time was more than 12 months. This study examined their clinical characteristics and relationships to patient outcomes. Results: A total of 1052 cases were included. There was an equal proportion of male and female (50.4% vs 49.6%). The mean age at the time of renal biopsy was 36.86 AE 11.58 years old. Five-year renal survival rate was 92%, and ten-year renal survival rate was 88%. We enrolled 297 cases who were followed up for 5 years. These patients were divided into rapid progression and stable progression according to the progress of renal function, we found that cases in rapid progression group had more proteinuria, higher blood pressure, poorer renal function, lower serum albumin and lower hemoglobin. When cases were divided according to CKD stage, the results showed no significant difference of outcomes among patients in CKD1-3a stages (P > 0.05). Their five-year renal survival rate was more than 95%. But patients in CKD3b-4 stage had worse outcomes. The five-year renal survival rate of patients in CKD3b stage was 85.3%, while it was only 65.3% in CKD 4 stage. Conclusion: Five-year renal survival rate of patients with primary IgAN was 92% in our hospital, and ten-year renal survival rate was 88%. Objective: Toll-like receptors (TLRs) are pattern associated receptors in innate immunity that may be involved in the recognition of self antigens and the production of pathogenic autoantibodies. The purpose of this study was to examine the expression and clinical significance of Toll-like Receptor 9 (TLR9) in peripheral blood B lymphocytes and kidney tissues from IgA nephropathy (IgAN) patients Methods: We measured TLR9 expression in the peripheral blood B lymphocytes in 200 IgAN patients and 100 healthy controls. TLR9 expression in the peripheral blood B lymphocytes was measured by in Flow cytometry. TLR9 expression in the kidney tissues was detected by immunohistochemical staining. IPP6.0 software was used to calculate the number of glomerulus crescent, and SPSS 17.0 statistical software was used to perform the statistical analysis. Results: Expression of TLR9 was increased in both peripheral blood B lymphocytes and kidney tissues from IgAN patients compared to the control groups. In addition, the expressions of renal tissue TLR9 were found to be significant negative correlated with urinary protein, and positive correlated with the number of glomerulus crescent and glomerular filtration rate. Conclusion: Elevated TLR9 levels were associated with the severity of renal function injury in IgAN patients. These findings help to clarify some of the clinical observations in the management of IgAN, and may highlight future directions for research. Methods: A retrospective cohort study was performed. Biopsy-proven IgAN patients with estimated glomerular filtration rate value higher than 15 ml/ min/1.73 m 2 at the time of renal biopsy were recruited. Clinical characteristics were collected during routine clinical practice. ESRD was defined by a need for renal replacement therapy (dialysis or renal transplantation). Cox regression was carried out to predict patient risk of ESRD and established a risk scoring system. Results: We analyzed 1,586 primary IgAN cases across 2 major nephrology centers with a mean follow-up time of 44.5 months (range 12e246 months), followed by validation in an independent cohort of 1,092 additional patients across 5 major nephrology centers. In total, the progression data were analyzed for 2,678 patients, of which 212 (8%) reached ESRD during follow-up. We identified five baseline clinical variables with an independent effect on the risk of ESRD, including gender, age, eGFR, urine protein and hemoglobin. We propose a simple bedside prediction tool based on our model. In the validation cohort, this model was more accurate than a simpler model that included eGFR, serum albumin, hemoglobin and systolic blood pressure [integrated discrimination improvement, 9.4% (4.9%, 13.9%); c Statistic 0.92 vs 0.90; and net reclassification improvement 9.2% (-4 Objective: The aim of this study is to explore its association with progression of IgA nephropathy (IgAN). Methods: Biopsy-proven primary IgAN patients with at least eGFR ! 15 ml/ min/1.73 m 2 at the time of biopsy and follow-up time ! 1 year were retrospectively recruited. Clinical, histological and progression data were recorded. Renal tissue was semi-quantitative scoredaccording to the Oxford scoring system. ABO blood group was determined by standard erythrocyte antiserum agglutination method. All patients were divided into B antigen group (type B and AB) and non-B antigen group (type A and O) based on their ABO types. Results: Among the 919 IgAN patients recruited in this study, 252 patients were type A (27.4%), 273 were type B (29.7%), 93 were type AB (10.1%) and 301 were type O (32.8%). When renal biopsy was performed, patients in B antigen group had higher eGFR (81.28 vs. 72.47 ml/min/1.73 m 2 ), lower systolic blood pressure (sbp) (125.26 vs. 128.77 mmHg) and uric acid (6.19 vs. 6.52 mg/dl) than patients in non-B antigen group. No significant difference was detected in histological lesions between these two groups. Totally, 124 patients (13.5%) progressed to end-stage renal disease (ESRD) after a median follow-up period of 57.46 months, including 42 (16.7%) type A, 23 (8.4%) type B, 3 (3.2%) type AB and 56 (18.6%) type O patients. Kaplan-Meier analysis showed that median ESRD-free survival time of patients in B antigen group was significantly longer than patients in non-B antigen group (159.05 AE 4.94 months vs. 143.09 AE 6.38 months, p < 0.001). Furthermore, patients in B antigen group were associated with a decreased risk of ESRD (HR Z 0.51, 95% CI 0.31e0.83) after being adjusted by age, sex, clinical and historical indicators (SBP, eGFR, blood urea nitrogen, serum albumin, uric acid, serum triglycerides, hemoglobin, serum C3, urine protein and Oxford Classification T). Conclusion: Our data suggest that B antigen had an independent protective effect against the progression of IgAN.
